| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 5078 | 2016 |
| CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment A Trotti, AD Colevas, A Setser, V Rusch, D Jaques, V Budach, C Langer, ... Seminars in radiation oncology 13 (3), 176-181, 2003 | 3219 | 2003 |
| Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer MR Posner, DM Hershock, CR Blajman, E Mickiewicz, E Winquist, ... New England Journal of Medicine 357 (17), 1705-1715, 2007 | 2141 | 2007 |
| Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial ML Gillison, AM Trotti, J Harris, A Eisbruch, PM Harari, DJ Adelstein, ... The Lancet 393 (10166), 40-50, 2019 | 1276 | 2019 |
| Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology DG Pfister, S Spencer, D Adelstein, D Adkins, Y Anzai, DM Brizel, ... Journal of the National Comprehensive Cancer Network 18 (7), 873-898, 2020 | 994 | 2020 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 798 | 2018 |
| NCCN guidelines insights: head and neck cancers, version 1.2018 AD Colevas, SS Yom, DG Pfister, S Spencer, D Adelstein, D Adkins, ... Journal of the National Comprehensive Cancer Network 16 (5), 479-490, 2018 | 600 | 2018 |
| First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers BI Sikic, N Lakhani, A Patnaik, SA Shah, SR Chandana, D Rasco, ... Journal of Clinical Oncology 37 (12), 946-953, 2019 | 529 | 2019 |
| E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of … S Marur, S Li, AJ Cmelak, ML Gillison, WJ Zhao, RL Ferris, WH Westra, ... Journal of Clinical Oncology 35 (5), 490-497, 2017 | 489 | 2017 |
| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ... Blood 109 (2), 399-404, 2007 | 469 | 2007 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 447 | 2017 |
| Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial NY Lee, Q Zhang, DG Pfister, J Kim, AS Garden, J Mechalakos, K Hu, ... The lancet oncology 13 (2), 172-180, 2012 | 393 | 2012 |
| Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma LB Nabors, T Mikkelsen, SS Rosenfeld, F Hochberg, NS Akella, JD Fisher, ... Journal of Clinical Oncology 25 (13), 1651-1657, 2007 | 383 | 2007 |
| NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines JJ Caudell, ML Gillison, E Maghami, S Spencer, DG Pfister, D Adkins, ... Journal of the National Comprehensive Cancer Network 20 (3), 224-234, 2022 | 378 | 2022 |
| Patient-reported outcomes and the evolution of adverse event reporting in oncology A Trotti, AD Colevas, A Setser, E Basch Journal of Clinical Oncology 25 (32), 5121-5127, 2007 | 375 | 2007 |
| NCCN guidelines insights: head and neck cancers, version 2.2017 D Adelstein, ML Gillison, DG Pfister, S Spencer, D Adkins, DM Brizel, ... Journal of the National Comprehensive Cancer Network 15 (6), 761-770, 2017 | 368 | 2017 |
| Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models JM Albert, C Cao, KW Kim, CD Willey, L Geng, D Xiao, H Wang, A Sandler, ... Clinical cancer research 13 (10), 3033-3042, 2007 | 345 | 2007 |
| Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy JJ Pan, WT Ng, JF Zong, LLK Chan, B O'Sullivan, SJ Lin, HCK Sze, ... Cancer 122 (4), 546-558, 2016 | 339 | 2016 |
| Ameloblastoma: a clinical review and trends in management AC McClary, RB West, AC McClary, JR Pollack, NJ Fischbein, ... European Archives of Oto-Rhino-Laryngology 273, 1649-1661, 2016 | 332 | 2016 |
| Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck AD Colevas Journal of Clinical Oncology 24 (17), 2644-2652, 2006 | 328 | 2006 |
